|
1
|
Travis WD, Linnoila RI, Tsokos MG,
Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H and
Doppman J: Neuroendocrine tumors of the lung with proposed criteria
for large-cell neuroendocrine carcinoma. An ultrastructural,
immunohistochemical, and flow cytometric study of 35 cases. Am J
Surg Pathol. 15:529–553. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosell R1, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, et al: Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Pas TM, Giovannini M, Manzotti M,
Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R and
Barberis M: Large-cell neuroendocrine carcinoma of the lung
harboring EGFR mutation and responding to gefitinib. J Clin Oncol.
29:e819–e822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Travis WD: Advances in neuroendocrine lung
tumors. Ann Oncol. 21:(Sul 7). vii65–vii71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Travis WD, Colby TV, Corrin B, et al:
Histological Typing of Lung and Pleural Tumors. Springer-Verlag;
Berlin: 1999, View Article : Google Scholar
|
|
7
|
Travis WD, Brambilla E, Müller-Hermelink
HK, et al: Pathology and GeneticsTumours of the Lung, Pleura,
Thymus and Heart. IARC Press; Lyon: 2004
|
|
8
|
Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim
HK, et al: Chemotherapy for pulmonary large cell neuroendocrine
carcinoma: Similar to that for small cell lung cancer or non-small
cell lung cancer? Lung Cancer. 77:365–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takei H, Asamura H, Maeshima A, Suzuki K,
Kondo H, Niki T, Yamada T, Tsuchiya R and Matsuno Y: Large cell
neuroendocrine carcinoma of the lung: A clinicopathologic study of
eighty-seven cases. J Thorac Cardiovasc Surg. 124:285–292. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fournel L, Falcoz PE, Alifano M,
Charpentier MC, Boudaya MS, Magdeleinat P, Damotte D and Régnard
JF: Surgical management of pulmonary large cell neuroendocrine
carcinomas: A 10-year experience. Eur J Cardiothorac Surg.
43:111–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abedallaa N, Tremblay L, Baey C, Fabre D,
Planchard D, Pignon JP, Guigay J, Pechoux CL, Soria JC, de
Montpreville VT, et al: Effect of chemotherapy in patients with
resected small-cell or large cell neuroendocrine carcinoma. J
Thorac Oncol. 7:1179–1183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kozuki T, Fujimoto N, Ueoka H, Kiura K,
Fujiwara K, Shiomi K, Mizobuchi K, Tabata M, Hamazaki S and
Tanimoto M: Complexity in the treatment of pulmonary large cell
neuroendocrine carcinoma. J Cancer Res Clin Oncol. 131:147–151.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Igawa S, Watanabe R, Ito I, Murakami H,
Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, et al:
Comparison of chemotherapy for unresectable pulmonary high-grade
non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Lung Cancer. 68:438–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yanagisawa S, Morikawa N, Kimura Y, Nagano
Y, Murakami K and Tabata T: Large-cell neuroendocrine carcinoma
with epidermal growth factor receptor mutation: Possible
transformation of lung adenocarcinoma. Respirology. 17:1275–1277.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Popat S, Wotherspoon A, Nutting CM,
Gonzalez D, Nicholson AG and O'Brien M: Transformation to ‘high
grade’ neuroendocrine carcinoma as an acquired drug resistance
mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer. 80:1–4.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rossi G, Cavazza A, Marchioni A, Longo L,
Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U,
et al: Role of chemotherapy and the receptor tyrosine kinases KIT,
PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine
carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iyoda A, Travis WD, Sarkaria IS, Jiang SX,
Amano H, Sato Y, Saegusa M, Rusch VW and Satoh Y: Expression
profiling and identification of potential molecular targets for
therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther
Med. 2:1041–1045. 2011.PubMed/NCBI
|
